FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155008672> ?p ?o ?g. }

• W2155008672 endingPage "1684" @default.
• W2155008672 startingPage "1675" @default.
• W2155008672 abstract "Purpose Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC. Patients and Methods The primary end point was the objective response rate. Secondary end points included response correlation with serum thyroglobulin (Tg); functional imaging; tumor genotype; and signaling inhibition in tumor biopsies. Using a Simon minimax two-stage design, 16 or 25 chemotherapy-naïve metastatic PTC patients were to be enrolled in arm A (accessible tumor for biopsy). Arm B patients had other subtypes of thyroid carcinoma or prior chemotherapy, and did not require tumor biopsies. Patients received 400 mg orally twice per day of sorafenib. Response was assessed every 2 months using RECIST (Response Evaluation Criteria in Solid Tumors). Results Of 41 PTC patients, six patients had a partial response (PR; 15%; 95% CI, 6 to 29) and 23 patients (56%; 95% CI, 40 to 72) had stable disease longer than 6 months. Median duration of PR was 7.5 months (range, 6 to 14). Median progression-free survival was 15 months (95% CI, 10 to 27.5). In 14 (78%) of 18 Tg-assessable PTC patients, Tg declined more than 25%. Common grade 3 adverse events included hand-foot skin reaction, musculoskeletal pain, and fatigue. BRAF mutation was detected in 17 (77%) of 22 PTCs analyzed. Four of 10 paired tumor biopsies from PTC patients showed a reduction in levels of vascular endothelial growth factor receptor phosphorylation, ERK phosphorylation, and in VEGF expression during sorafenib therapy. No PRs were noted among non-PTC patients. Conclusion Sorafenib is reasonably well-tolerated therapy with clinical and biologic antitumor activity in metastatic PTC." @default.
• W2155008672 created "2016-06-24" @default.
• W2155008672 creator A5002114331 @default.
• W2155008672 creator A5016175407 @default.
• W2155008672 creator A5017479061 @default.
• W2155008672 creator A5027165899 @default.
• W2155008672 creator A5029524605 @default.
• W2155008672 creator A5035552610 @default.
• W2155008672 creator A5050821972 @default.
• W2155008672 creator A5051619378 @default.
• W2155008672 creator A5053410398 @default.
• W2155008672 creator A5058456767 @default.
• W2155008672 creator A5064088482 @default.
• W2155008672 creator A5067136663 @default.
• W2155008672 creator A5070614030 @default.
• W2155008672 creator A5074454934 @default.
• W2155008672 creator A5082225634 @default.
• W2155008672 creator A5087489933 @default.
• W2155008672 creator A5091557207 @default.
• W2155008672 date "2009-04-01" @default.
• W2155008672 modified "2023-10-04" @default.
• W2155008672 title "Phase II Trial of Sorafenib in Metastatic Thyroid Cancer" @default.
• W2155008672 cites W1508497000 @default.
• W2155008672 cites W1967824042 @default.
• W2155008672 cites W1972166687 @default.
• W2155008672 cites W1982246723 @default.
• W2155008672 cites W1994953133 @default.
• W2155008672 cites W2029409133 @default.
• W2155008672 cites W2061903640 @default.
• W2155008672 cites W2066467575 @default.
• W2155008672 cites W2070563197 @default.
• W2155008672 cites W2087916660 @default.
• W2155008672 cites W2100378386 @default.
• W2155008672 cites W2103255787 @default.
• W2155008672 cites W2104875539 @default.
• W2155008672 cites W2106555100 @default.
• W2155008672 cites W2106695112 @default.
• W2155008672 cites W2109787198 @default.
• W2155008672 cites W2115593978 @default.
• W2155008672 cites W2125153669 @default.
• W2155008672 cites W2125385057 @default.
• W2155008672 cites W2136656327 @default.
• W2155008672 cites W2139248078 @default.
• W2155008672 cites W2142752142 @default.
• W2155008672 cites W2149026055 @default.
• W2155008672 cites W2151747343 @default.
• W2155008672 cites W2152941400 @default.
• W2155008672 cites W2156871508 @default.
• W2155008672 cites W2157875025 @default.
• W2155008672 cites W2158801409 @default.
• W2155008672 cites W2171003891 @default.
• W2155008672 cites W2171379946 @default.
• W2155008672 cites W4253705647 @default.
• W2155008672 doi "https://doi.org/10.1200/jco.2008.18.2717" @default.
• W2155008672 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2668972" @default.
• W2155008672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19255327" @default.
• W2155008672 hasPublicationYear "2009" @default.
• W2155008672 type Work @default.
• W2155008672 sameAs 2155008672 @default.
• W2155008672 citedByCount "500" @default.
• W2155008672 countsByYear W21550086722012 @default.
• W2155008672 countsByYear W21550086722013 @default.
• W2155008672 countsByYear W21550086722014 @default.
• W2155008672 countsByYear W21550086722015 @default.
• W2155008672 countsByYear W21550086722016 @default.
• W2155008672 countsByYear W21550086722017 @default.
• W2155008672 countsByYear W21550086722018 @default.
• W2155008672 countsByYear W21550086722019 @default.
• W2155008672 countsByYear W21550086722020 @default.
• W2155008672 countsByYear W21550086722021 @default.
• W2155008672 countsByYear W21550086722022 @default.
• W2155008672 countsByYear W21550086722023 @default.
• W2155008672 crossrefType "journal-article" @default.
• W2155008672 hasAuthorship W2155008672A5002114331 @default.
• W2155008672 hasAuthorship W2155008672A5016175407 @default.
• W2155008672 hasAuthorship W2155008672A5017479061 @default.
• W2155008672 hasAuthorship W2155008672A5027165899 @default.
• W2155008672 hasAuthorship W2155008672A5029524605 @default.
• W2155008672 hasAuthorship W2155008672A5035552610 @default.
• W2155008672 hasAuthorship W2155008672A5050821972 @default.
• W2155008672 hasAuthorship W2155008672A5051619378 @default.
• W2155008672 hasAuthorship W2155008672A5053410398 @default.
• W2155008672 hasAuthorship W2155008672A5058456767 @default.
• W2155008672 hasAuthorship W2155008672A5064088482 @default.
• W2155008672 hasAuthorship W2155008672A5067136663 @default.
• W2155008672 hasAuthorship W2155008672A5070614030 @default.
• W2155008672 hasAuthorship W2155008672A5074454934 @default.
• W2155008672 hasAuthorship W2155008672A5082225634 @default.
• W2155008672 hasAuthorship W2155008672A5087489933 @default.
• W2155008672 hasAuthorship W2155008672A5091557207 @default.
• W2155008672 hasBestOaLocation W21550086721 @default.
• W2155008672 hasConcept C121608353 @default.
• W2155008672 hasConcept C126322002 @default.
• W2155008672 hasConcept C143998085 @default.
• W2155008672 hasConcept C203092338 @default.
• W2155008672 hasConcept C2776694085 @default.
• W2155008672 hasConcept C2778019345 @default.
• W2155008672 hasConcept C2778695046 @default.

• next